Close Menu

circulating tumor DNA

Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.

The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 15 skipping alterations.

The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.

A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.

The company has overcome one major hurdle and is poised to clear another in the first half of this year, clearing the way for new test development.

The firm said its revenues for the three months ended Dec. 31, 2019 were $62.9 million compared to $32.9 million in the same quarter of 2018.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.

The group aims to develop a transcriptomic and epigenetic biomarker assay for early detection and relapse monitoring in colorectal cancer patients. 

The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.

Pages